The Quantification of ERK2 Activation on the Basis of Cell Equivalents by Densitometry Is Shown for Data Presented in Fig3
| Agonists . | Control [%] . | Panel . | ||
|---|---|---|---|---|
| I Preincubation Sphingosine [%] . | II Sphingosine Alone [%] . | III DiC10 Alone [%] . | ||
| (A) fMLP + EIgG | 100 | 87 ± 12* | <5* | 132 ± 14† |
| (B) EIgG | 49 ± 18* | 59 ± 14* | 0* | 108 ± 19‡ |
| (C) Unstimulated | 0* | 13 ± 6† | 0 | 97 ± 16‡ |
| (D) fMLP | 63 ± 17* | 75 ± 10‡ | <5* | 114 ± 27‡ |
| Agonists . | Control [%] . | Panel . | ||
|---|---|---|---|---|
| I Preincubation Sphingosine [%] . | II Sphingosine Alone [%] . | III DiC10 Alone [%] . | ||
| (A) fMLP + EIgG | 100 | 87 ± 12* | <5* | 132 ± 14† |
| (B) EIgG | 49 ± 18* | 59 ± 14* | 0* | 108 ± 19‡ |
| (C) Unstimulated | 0* | 13 ± 6† | 0 | 97 ± 16‡ |
| (D) fMLP | 63 ± 17* | 75 ± 10‡ | <5* | 114 ± 27‡ |
For comparative purposes, the extent of fMLP-primed PMN (2 × 106/mL) undergoing phagocytosis with EIgG was determined to be 100%. Comparisons were made between sphingosine-treated PMN (panel II) versus sphingosine with DiC10-treated PMN (panel I), between control values versus sphingosine-treated PMN (panel II) and DiC10-treated PMN (panel III), and between different control values (A v B, C, and D).
P < .0001.
P < .05.
P < .001.